Antibacterial Agents TRIZ Cases

Peptide amphiphile molecules self-assemble into aligned nanofiber bundles through temperature-controlled phase transitions.

Segmented antisense oligonucleotides target natural antisense transcripts to resolve specificity and complexity trade-offs in HGF modulation.

Affinity purification isolates high-affinity molecular imprinted polymer particles, resolving low specificity that limits clinical use.

Short cationic peptides overcome biofilm resistance by disrupting extracellular matrices and cell membranes via amphiphilic structures.

AF-17 peptide employs reversible cysteine disulfide bonds to resist peptidase degradation, extending half-life for therapeutic applications.

Electrostatic drug delivery particles enable sustained release of antimicrobials via inhalation, targeting dormant bacteria to shorten treatment duration.

Targeted biaryl substitutions on glycopeptide antibiotics expand the spectrum of action against vancomycin-resistant strains.

A stereoselective process using Evans oxazolidinone auxiliaries yields highly crystalline quinazoline derivatives for tyrosine kinase inhibition.

Peptides bind scurfin to inhibit regulatory T cells, reducing autoimmune risk while enhancing antitumor immunity.

A pharmaceutical composition containing 3-hydroxyanthranilic acid and an iron chelator or supplement targets bacterial growth inhibition.

Segmented pH-responsive coatings protect probiotics from duodenal degradation, ensuring targeted release in the ileum to restore intestinal balance.

Fusion proteins combine antigen binding with intracellular signaling domains to activate T cells.

Cyclodextrin-containing polymers bind nucleic acids to inhibit Toll-like receptor activation, addressing redundancy in inflammatory pathways.

Defining exactly two sulfomethyl groups per molecule resolves toxicity and inconsistent therapeutic levels in commercial polymyxin mixtures.

Combining CRISPR endonucleases with Gam proteins blocks RecBCD-mediated DNA repair, preventing bacterial survival after chromosomal cleavage.

Segmenting calixarene cores with rigid amide linkers resolves low affinity bottlenecks to block Pseudomonas aeruginosa LecA and LecB interactions.

Benzene polycarboxylic acid polymers complex with platinum to reduce nephrotoxicity while maintaining anti-cancer efficacy.

Benzoxazinone derivatives inhibit long-chain fatty acyl elongase, reducing fatty acid accumulation to treat metabolic syndrome and diabetes.

A Bordetella pertussis vaccine composition uses genetically detoxified toxins and virulence factors to induce neutralizing antibodies.

Solid support implants with trans-cyclooctene and tetrazine linkers enable precise agent accumulation at target tissues.

Nitro-substituted aromatic sulfonyl fluoride pharmacophores overcome low membrane permeability barriers in Gram-negative bacteria.

Alkyl glycosides replace toxic parabens with deoxyaldohexose structures to provide effective antimicrobial protection without harmful side effects.

Halogenated salicylanilides like niclosamide treat resistant Staphylococcus aureus infections while significantly lowering spontaneous mutant resistance rates.

Tripeptide epoxy ketone compounds reduce cytokine production and antigen presentation by selectively inhibiting immunoproteasome subunits.

Semifluorinated alkanes penetrate the impermeable nail plate barrier to deliver therapeutic drug concentrations directly to the nail matrix.

Phage tailspike protein digests exopolysaccharides into homogeneous oligosaccharide fragments for glycoconjugate vaccine coupling.

Modified pleuromutilin compounds featuring hydroxyamino or acyloxyaminocycloalkyl groups enhance antimicrobial potency against diverse bacterial strains.

Hyperimmunized egg product containing IgY antibodies neutralizes Clostridium perfringens toxins, avoiding antibiotic resistance in poultry production.

Engineered humanized antibodies block PD-L1 interactions, overcoming immune tolerance to enhance antitumor immunity.

Glycoproteins gp36 and gp47 elicit strong antibody responses, overcoming inadequate targeting of immunoreactive glycoproteins in current diagnostics.

Sortase enzymes enable site-specific payload attachment to antibodies, resolving stochastic mixture issues and ensuring consistent therapeutic efficacy.

Ring constrained boron compounds enhance arginase inhibition efficacy to treat diseases linked to nitric oxide imbalance.

IgM protease antigen vaccine overcomes serotype-specific immunity limits by providing heterologous protection against multiple Streptococcus suis strains.

Terminal chemical modifications improve polypeptide efficacy against infections where natural sequences show insufficient activity.

Dynamic dosing adjustments based on creatinine clearance prevent toxic drug accumulation while sustaining therapeutic efficacy in hemodialysis patients.

Hypohalous acid eliminates microbial resistance and toxicity by oxidizing cell structures without irritation.

Extracted FcRn binding motif extends half-life without increasing size or immunoreactivity, resolving trade-offs in tissue penetration.

Bile salt intermediary enhances antibiotic penetration through gastric mucus to overcome poor mucosal concentration and improve eradication efficacy.

Merges multiple probiotic strains into a single feed additive to reduce mortality and necrotic enteritis lesions while simplifying treatment regimens.

Cellular microvesicles transport siRNA to target cells via lipid bilayer interactions.

Optimizing piperidine substituent patterns improves CCR3 binding affinity while reducing off-target side effects.

Mannitol and divalent cation salts protect GCC agonist peptides from chemical degradation in gastric juices, enabling effective low-dose treatment.

Hydrophobic modifications at the Tpg4 position reinstate binding affinity to D-Ala-D-Lac, overcoming resistance mechanisms in vancomycin-resistant bacteria.

Immunogenic composition combines Group A Streptococcus polypeptide antigens with a polypeptide-polysaccharide conjugate lacking immunodominant side chains.

Substituted estra-tetraene carboxamides selectively inhibit AKR1C3 while avoiding CYP17A1 interference and improving aqueous solubility.

Soluble ActRII polypeptides antagonize receptors to treat muscular dystrophy and obesity.

Substituted tetrazolyl sulfonamide compounds inhibit metallo-beta-lactamase enzymes to protect beta-lactam antibiotics from degradation.

Proteasome inhibition accumulates defective ribosomal products in secreted blebs, resolving rapid antigen degradation that limits immunotherapy efficacy.